MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202

News   Dec 06, 2012

 
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
 
 
 

RELATED ARTICLES

British Pharmacological Society’s Drug Discovery of the Year 2018 Announced

News

A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.

READ MORE

Inflammation Causes Chemo Brain

News

The research could lead to a new practice of identifying inflammatory biomarkers in cancer patients and then treating the inflammation with medications or exercise to improve cognition and other symptoms.

READ MORE

What Does the Future of Vaccines and Immunotherapy Look Like?

News

Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE